IBDEI14V ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20301,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,20302,0)
 ;;=289.89^^131^1286^15
 ;;^UTILITY(U,$J,358.3,20302,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20302,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,20302,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,20302,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,20303,0)
 ;;=238.79^^131^1286^88
 ;;^UTILITY(U,$J,358.3,20303,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20303,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,20303,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,20303,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,20304,0)
 ;;=287.30^^131^1286^110
 ;;^UTILITY(U,$J,358.3,20304,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20304,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,20304,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,20304,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,20305,0)
 ;;=288.09^^131^1286^8
 ;;^UTILITY(U,$J,358.3,20305,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20305,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,20305,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,20305,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,20306,0)
 ;;=V10.21^^131^1286^61
 ;;^UTILITY(U,$J,358.3,20306,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20306,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,20306,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,20306,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,20307,0)
 ;;=284.2^^131^1286^106
 ;;^UTILITY(U,$J,358.3,20307,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20307,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,20307,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,20307,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,20308,0)
 ;;=202.40^^131^1286^76
 ;;^UTILITY(U,$J,358.3,20308,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20308,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,20308,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,20308,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,20309,0)
 ;;=287.49^^131^1286^118
 ;;^UTILITY(U,$J,358.3,20309,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20309,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,20309,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,20309,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,20310,0)
 ;;=180.9^^131^1286^29
 ;;^UTILITY(U,$J,358.3,20310,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20310,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,20310,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,20310,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,20311,0)
 ;;=203.02^^131^1286^104
 ;;^UTILITY(U,$J,358.3,20311,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20311,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,20311,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,20311,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,20312,0)
 ;;=204.02^^131^1286^2
 ;;^UTILITY(U,$J,358.3,20312,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20312,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,20312,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,20312,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,20313,0)
 ;;=204.12^^131^1286^17
 ;;^UTILITY(U,$J,358.3,20313,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20313,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,20313,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,20313,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,20314,0)
 ;;=204.20^^131^1286^114
 ;;^UTILITY(U,$J,358.3,20314,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20314,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,20314,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,20314,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,20315,0)
 ;;=204.21^^131^1286^116
 ;;^UTILITY(U,$J,358.3,20315,1,0)
 ;;=^358.31IA^5^2
